MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Atidarymo kaina

17.88 17.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.09

Max

16.78

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.5M -29M
Darbuotojai	103
EBITDA	-2M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+0.47% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	442M 5.3B
Ankstesnė atidarymo kaina	0.48
Ankstesnė uždarymo kaina	17.88

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-13 23:25; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026-04-13 22:45; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026-04-13 18:03; UTC

Uždarbis

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026-04-13 23:58; UTC

Uždarbis

Review & Preview: Earnings Time -- Barrons.com

2026-04-13 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026-04-13 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026-04-13 23:20; UTC

Rinkos pokalbiai

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026-04-13 23:01; UTC

Uždarbis

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026-04-13 23:01; UTC

Uždarbis

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026-04-13 23:01; UTC

Uždarbis

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026-04-13 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026-04-13 21:26; UTC

Svarbiausios naujienos

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026-04-13 21:16; UTC

Uždarbis

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026-04-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-13 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026-04-13 19:59; UTC

Rinkos pokalbiai

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026-04-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026-04-13 19:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Precious Metals Market Talk on April 9

2026-04-13 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026-04-13 18:43; UTC

Rinkos pokalbiai

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

0.47% į viršų

12 mėnesių prognozė

Vidutinis 17.09 USD 0.47%

Aukščiausias 25 USD

Žemiausias 2 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.